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Summary Vascular endothelial growth factor (VEGF) is known to be produced by various solid tumours and is thought to be involved in
microvascular permeability and/or angiogenesis. To examine the relationship between VEGF expression in ovarian neoplasms and
clinicopathological factors or patient survival, expression of VEGF was analysed immunohistochemically in 110 epithelial ovarian tumours. In
addition, VEGF levels in the tumour fluid (17 patients), ascites (12 patients) and sera (38 patients) were determined using enzyme
immunoassay. Positive immunostaining for VEGF was observed in 97% (68 out of 70) of ovarian carcinomas, which was significantly higher
than that of tumours of low malignant potential (LMP) (13 out of 25; 52%) and benign cystadenomas (5 out of 15; 33%) (P < 0.01). In ovarian
carcinomas, strong VEGF immunostaining was also observed more frequently in tumours of clear cell type (P < 0.05) in the advanced stage
of disease (P< 0.05) and with positive peritoneal cytology (P< 0.01). Patients with strong VEGF staining had poorer survival rates than those
with weak or no immunostaining for VEGF (P < 0.01). These findings suggest that strong VEGF expression plays an important role in the
tumour progression of ovarian carcinoma. The enzyme immunoassay revealed higher serum VEGF levels in carcinoma patients than those
in patients with LMP or benign tumours (P< 0.01). Serum VEGF levels decreased after the successful removal of tumours in ovarian cancer
patients and, in one patient, the serum VEGF level was re-elevated during relapse. Therefore, serum VEGF could be used as a marker for
monitoring the clinical course of ovarian cancer patients.
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Vascular endothelial growth factor (VEGF), also known as
vascular permeability factor (VPF), is a multifunctional cytokine
that increases microvascular permeability and directly stimulates
endothelial cell growth and angiogenesis (Senger et al, 1993), as
the specific receptors for VEGF are expressed in vascularendothe-
lial cells (Neufeld et al, 1994). VEGF has been reported to be
synthesized and secreted by a variety of cultured tumour cells
(Senger et al, 1986) and human solid tumours, such as brain
tumours (Plate et al, 1992; Berkman et al, 1993; Samoto et al,
1995), lung cancers (Mattem et al, 1996), breast carcinomas
(Brown et al, 1995), gastrointestinal tract adenocarcinomas
(Brown et al, 1993a), renal and bladder carcinomas (Brown et al,
1993b; Takahashi et al, 1994) and epithelial ovarian carcinomas
(Olson et al, 1994; Boocock et al, 1995; Abu-Jawdeh et al, 1996).
Increased expression of VEGF has been suggested to be involved
in tumorigenesis, metastasis and the production ofmalignant effu-
sion via the enhancement ofvascular permeability or angiogenesis
(Senger et al, 1993; Neufeld et al, al, 1994).
Ovarian carcinoma is the leading cause of death in female
genital malignancies, and more than half of the patients are diag-
nosed at the advanced stage of the disease (NIH, 1994). The
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common pathway of tumour progression in ovarian carcinomas is
peritoneal dissemination, and the progressive accumulation of
ascites is frequent with or without malignant tumour cells in the
peritoneal fluid. It has been reported recently that ovarian carci-
nomas express VEGF mRNA and VEGF protein (Olson et al,
1994; Boocock et al, 1995; Abu-Jawdeh et al, 1996). Whether the
level of VEGF expression is different among benign cystade-
nomas, tumours oflow malignant potential (LMP) and carcinomas
(Abu-Jawdeh et al, 1996) is still unclear. Correlations between the
expression of VEGF and the histological type, stage of disease,
ascitic volume and peritoneal cytology in ovarian carcinomas
have not been reported. We therefore examined the expression of
VEGF in various types ofepithelial ovarian neoplasm by immuno-
histochemistry and analysed the correlation with various clinico-
pathological factors and patient survival.
VEGF has been reported to be present in human peritoneal and
pleural effusions under tumour and inflammatory conditions
(Yeo et al, 1993; Krasnow et al, 1996). As VEGF is known to
increase vascular permeability, when substantial amounts of
VEGF are present in the tumour fluid (Abu-Jawdeh et al, 1996) or
ascitic fluid (Yeo et al, 1993), VEGF itself may be released into
the patients' serum. If serum VEGF is assayable, VEGF may be a
possible tumour marker for ovarian cancer patients. To address
this hypothesis, we also analysed VEGF concentrations in the
tumour fluid, ascitic fluid and sera ofpatients with various epithe-
lial ovarian tumours using an enzyme immunoassay.
12211222 S Yamamoto etal
MATERIALS AND METHODS
Patients and tissues
Fresh surgical specimens of epithelial ovarian tumours were
obtained from 110 women who underwent laparotomy at Kyoto
University Hospital between 1981 and 1995. Informed consent
was obtained from each patient according to the Guidelines ofthe
Ethical Committee (no. 92) of Kyoto University Faculty of
Medicine. Histologically, 15 ofthe 110 cases were benign cystade-
nomas (seven serous, eight mucinous benign tumours), 25 were
tumours of low malignant potential (eight serous, 17 mucinous
LMP tumours) and 70 were carcinomas (27 serous, 13 mucinous,
14 endometrioid, 16 clear cell carcinomas). According to the
classification of the International Federation of Gynecology and
Obstetrics (FIGO), the 70 patients with ovarian carcinoma
consisted of32 stage I, five stage II, 25 stage III and eight stage IV
patients. Ascitic volume at laparotomy was 500 ml or less in 47,
and more than 500 ml in 23 of the 70 patients with carcinoma.
Peritoneal cytology was evaluated in 60 ofthe 70patients; 37 were
negative and 23 were positive for malignant cells. All of the 70
carcinomapatients were given more than four courses ofcisplatin-
based chemotherapy after surgery.
The tissues for immunohistochemistry for VEGF, obtained
immediately after the surgical procedure, were fixed in 10%
buffered formalin and embedded in paraffin. Patient sera before
and after surgery, ascitic fluids and tumour fluids for the VEGF
assay were available in 38 patients (ten benign cystadenomas,
seven LMP tumours and 21 carcinomas). Tumour fluids were
those present in the cystic space of ovarian tumours and were
obtained immediately after the tumour extirpation. Control sera
were also obtained from six women with no apparent gynaeco-
logical diseases. The fluid samples were stored at -80°C after
centrifugation at 1500 r.p.m. for 15 min.
Immunohistochemistry
Immunostaining ofthe paraffin-embedded sections was performed
by the avidin-biotin-peroxidase complex method using a
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA,
USA). Briefly, 6-im sections were deparaffinized and incubated in
phosphate-buffered saline (PBS) containing 0.1% saponin for
30 min. They were then treated with 0.3% hydrogen peroxide and
incubated with 10% normal goat serum to block non-specific
binding. The sections were then incubated with rabbit anti-
human VEGF polyclonal antibody (diluted 1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or control rabbit serum at
room temperature for 2 h. They were then washed in PBS and
exposed to biotinylated goat anti-rabbit IgG, followed by treatment
with the avidin-peroxidase complex and stained with diamino-
benzidine with 0.15% hydrogen peroxide. Counterstaining was
performed with haematoxylin. Sections of uterine myometrium
were used as a positive control, as vascular pericytes and smooth
muscle cells are known to express VEGF (Harrison-Woolrych et al,
1995). VEGF immunoreactivity was observed in the cytoplasm of
the tumour cells. No equivalent staining was observed when the
primary antibody was replaced by control antibody. The grade of
immunostaining was assessed by two independent observers, based
on both the staining intensity (negative, faintly stained or intensely
stained) and the number of positive cells (0%, 50% or less, more
than 50%). The results of immunostaining were classified as
negative (-) when there were no positive cells, weakly positive (+)
when the staining was faint or the positive cells were 50% or less,
and strongly positive (++) when the number of intensely stained
cells was greater than 50%.
The anti-human VEGF antibody (A-20) is an affinity-purified
rabbitpolyclonal antibodyraised against a 20 amino acid synthetic
peptide corresponding to residues 1-20, which map to the amino
terminus of human VEGF. This antibody is reported to react
specifically with VEGF of mouse, rat and human origin and has
been used previously for immunohistochemical investigation of
VEGF localization in normal and neoplastic human tissues
(Boocock et al, 1995; Harrison-Woolrych et al, 1995; Kamat et al,
1995; Neulen et al, 1995; Gordon et al, 1996).
Enzyme immunoassay
A VEGF assay was performed using a Sandwich Enzyme
Immunoassay kit for human VEGF (ImmunoBiological
Laboratories, Fujioka, Gumma, Japan) according to the manufac-
turer's instructions. Briefly, 50gl of samples diluted in 100 pl of
buffer solution and serially diluted standard solution (human
VEGF from Sf21 cells) were added to each well of the 96-well
microtitre plate coated with mouse anti-human VEGF monoclonal
antibody and were incubated for 1 h at 370C. For dilution, PBS
containing 1% bovine serum albumin (BSA) and 0.05% Tween
was used. After washing the wells five times with PBS, 100 pl of
horseradish peroxidase (HRP)-conjugated Fab' of the affinity-
purified rabbit anti-human VEGF IgG diluted with the buffer was
added to each well and was incubated for 30 min at 370C. Wells
were washed five times with PBS, then the enzyme reaction was
carried out at room temperature for 30 min with diaminobenzidine
with 0.03% hydrogen peroxide. The chemiluminescence of the
wells was measured at 492 nm of absorbance by a plate lumi-
nometer, and the VEGF contents of the samples were estimated
from the standard curve determined from the serially diluted stan-
dard VEGF solution.
Statistical analysis
Thechi-square test and Fisher's two-tailed exact test were applied to
assess the correlation between immunoreactivity and the clinico-
pathological factors of ovarian tumour patients. Survival curves
of ovarian carcinoma patients were generalized using the
Kaplan-Meier method, and the prognosis of two groups was
comparedby generalized Wilcoxon's analysis. Multivariate analysis
of the prognosis was performed using the Cox regression model
(Cox, 1972). For the analysis ofthe results of the VEGF assay, we
used the Mann-Whitney U-test and Spearman's rank correlation.
RESULTS
Immunohistochemistry of VEGF in benign and LMP
ovarian tumours
Immunohistochemical results are summarized in Table 1. Among
the 15 benign cystadenomas, ten (67%) were negative (Figure IA),
four (27%) were weakly positive and one (7%) was strongly posi-
tive for VEGF. Histologically, immunoreactivity for VEGF was
observed in four of the seven serous tumours and one of the eight
mucinous tumours. Of the 25 LMP ovarian tumours, 12 (48%)
were negative, 11 (44%) were weakly positive (Figure iB) and
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Table 1 VEGF immunostaining in epithelial ovarian neoplasms
Total number of cases VEGF immunostaining
(-) (+) (++)
Benign cystadenomas 15 10 (67) 4 (27) 1 (7)
Serous 7 3 (43) 3 (43) 1 (14)
Mucinous 8 7 (88) 1 (13) 0 (0)
LMP tumours 25 12 (48) 11 (44) 2 (8)
Serous 8 2 (25) 5 (63) 1 (13)
Mucinous 17 10 (59) 6 (35) 1 (6)
Carcinomas 70 2 (3) 29 (41) 39 (56)
Histological type
Serous 27 0 (0) 13 (48) 14 (52)
Mucinous 13 1 (8) 8 (62) 4 (31)
Endometrioid 14 0 (0) 6 (43) 8 (57)
Clearcell 16 1 (6) 2 (13) 13 (81)
FIGO stage
32 1 (3) 19 (59) 12 (38)
11 5 0 (0) 1 (20) 4 (80)
III 25 0 (0) 9 (36) 16 (64)
IV 8 1 (13) 0 (0) 7 (88)
Ascitic volume
<500 ml 47 2 (4) 24 (51) 21 (45)
>500 ml 23 0 (0) 7 (30) 16 (70)
Ascitic cytology
Negative 37 1 (3) 23 (62) 13 (35)
Positive 23 0 (0) 6 (26) 17 (74)
VEGF, vascular endothelial growth factor; LMP, low malignant potential; FIGO, International Federation of Gynecology
and Obstetrics. Numbers in parentheses are percentages.
two (8%) were strongly positive for VEGF. Histologically, VEGF
immunostaining was positive in six of the eight serous LMP
tumours and in 7 ofthe 17 mucinous ovarian tumours. The rate of
VEGF positivity did not significantly differ between benign and
LMP tumours. Mucinous epithelia in benign and LMP tumours
were frequently associated with the luteinized theca-like cells in
the underlying stroma. These luteinized stromal cells were
strongly positive for VEGF, irrespective ofthe VEGF positivity in
the tumour cells (Figure IA).
Immunohistochemistry of VEGF in ovarian carcinomas
Among the 70 ovarian carcinomas, two (3%) were negative, 29
(41%) were weakly positive and 39 (56%) were strongly positive
for VEGF (Figure IC and D) (Table 1). The frequency of VEGF
positivity in ovarian carcinomas (68 out of 70; 97%) was signifi-
cantly higher than that in benign (5 out of 15; 33%) and LMP
(13 out of25; 52%) ovarian tumours (P < 0.01). The rate of strong
VEGF immunostaining was also significantly higher in carci-
nomas (39 out of70; 56%) than that in benign (1 out of 15; 7%) or
LMP (2 out of25; 8%) tumours (P < 0.01).
According to the histological type, strong immunostaining for
VEGF was observed in 14 ofthe 27 serous (52%), 4 ofthe 13 muci-
nous (31%), 8 ofthe 14 endometrioid (57%) and 13 ofthe 16 clear
cell (81%) carcinomas. The frequency of strong VEGF immuno-
reactivity in clear cell carcinomas (Figure ID) was significantly
higher than that in other histological tumour types (P < 0.05).
As regards the FIGO stage classification, strong immuno-
staining for VEGF was found in 12 ofthe 32 (38%) stage I, fourof
the five (80%) stage II, 16 of the 25 (64%) stage III and seven of
the eight (88%) stage IV carcinomas. There was a significant rela-
tionship between strong VEGF immunoreactivity and the FIGO
stage of disease (P < 0.05). With regards to the ascitic volume,
strong VEGF immunostaining was more frequently seen in
patients with ascites ofmore than 500 ml (16 out of23; 70%) than
those with ascites of 500 ml or less (21 out of45; 45%), although
the difference was not statistically significant. Among the 60 cases
in which ascitic cytology was available, strong VEGF immuno-
staining was observedin 13 ofthe 37 (35%) withnegativecytology,
but in 17 ofthe 23 (74%) with positive cytology (P < 0.01).
VEGF expression and patient survival in ovarian
carcinomas
In the 70 patients with ovarian carcinoma, the prognostic signifi-
cance of VEGF immunostaining was analysed using the
Kaplan-Meier method. Patients with strong VEGF immuno-
staining showed poorer survival that those with weak or no
immunoreactivity for VEGF (P < 0.01) (Figure 2). Multivariate
analysis including other prognostic factors, such as age, histolog-
ical type, FIGO stage and residual tumour size, showed that only
the FIGO stage was a significant prognostic factor (P = 0.006) and
that VEGF immunoreactivity was not an independent prognostic
indicator.
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Figure 1 Immunohistochemical staining of VEGF in ovarian tumours. (A) Benign mucinous cystadenoma. Tumour cells are negative for VEGF, whereas the
luteinized theca-like cells in the stroma are strongly positive for VEGF (arrows). (B) Serous LMP tumour showing weak VEGF immunostaining (arrows). (C)
Endometrioid carcinoma. Tumour cells are strongly immunostained for VEGF. (D) Clear cell carcinoma. Tumour cells of both clear cell and hobnail types are
intensely immunostained for VEGF (x400).
Enzyme immunoassay of VEGF in tumour fluid, ascites
and patient sera
Results of the enzyme immunoassay of 38 patients are listed in
Table 2. VEGF levels in the tumour fluid were assayed in 17 cases
(five benign cystadenomas, four LMP tumours and eight carci-
nomas). VEGF levels in the tumour fluid ranged between 47 and
4111 pg ml-' (mean ± s.d. 1662 ± 2076) in benign tumours, between
250 and 5187 pg ml' (mean ± s.d. 2739 ± 1196) in LMP tumours
and between 494 and 23 790 pg ml' (mean ± s.d. 10 908 ± 9 576) in
carcinomas. In benign and LMP tumours, VEGFlevels ofmore than
1000 pg ml-' in the tumour fluid were seen in five of the six muci-
nous tumours, but in none ofthe three serous tumours. Tumour fluid
VEGF levels in carcinomas were significantly higher than those of
British Journal of Cancer (1997) 76(9), 1221-1227
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Figure 2 Survival curves of ovarian carcinoma patients generated by the
Kaplan-Meier method according to VEGF immunoreactivity
benign tumours (P < 0.05). VEGF levels in the ascitic fluid were
available in 12 carcinoma patients and ranged between 44 and
14 336 pg ml' (mean ± s.d. 2971 ± 4025).
The serum VEGF levels ranged between 0 and 246 pg ml'
(mean s.d. 90 ± 92) in control women, between 0 and 236 pg ml
(mean s.d. 73 ± 85) in ten patients with benign cystadenoma,
between 0 and 283 pg ml (mean ± s.d. 101 ± 98) in seven patients
with LMP tumours and between 0 and 890 pg ml' (mean ± s.d.
295 ± 237) in 20 patients with carcinoma (Table 2). Serum VEGF
levels in carcinoma patients were significantly higher than those of
control women and of patients with LMP or benign tumours
(P < 0.01), although there were a few carcinoma patients whose
serum VEGF levels were unexpectedly low. Serum VEGF levels
were not linearly correlated with either ascitic levels or tumour
fluid levels. When the cut-offlevel of serum VEGF was arbitrarily
defined as 250 pg ml' because none ofthe control group exceeded
this value, increased serum VEGF levels (> 250 pg ml-') were
Table 2 VEGF levels in the tumour fluid, ascites and sera from the patients with epithelial ovarian neoplasms
Patient no. Age Histological type Stage VEGF (pg ml-') CA 125
Tumour Ascites Serum (U ml-,)
Benign cystadenoma
1 51
2 22
3 34
4 41
5 54
6 56
7 30
8 31
9 63
10 21
LMP tumour
11
12
13
14
15
16
17
Carcinoma
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
78
36
30
72
52
46
21
31
63
54
48
69
71
66
26
39
46
64
71
31
45
44
61
67
68
45
72
52
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Mucinous
Mucinous
Mucinous
Serous
Mucinous
Mucinous
Mucinous
Mucinous
Mucinous
Mucinous
(1662±2076)
47
211
ND
ND
ND
ND
ND
190
4111
3752
IA
IA
IA
IA
IA
IA
IA
Mucinous
Clear cell
Clear cell
Clear cell
Clear cell
Endometrioid
Serous
Serous
Serous
Serous
Serous
Serous
Endometrioid
Endometrioid
Serous
Serous
Serous
Serous
Endometrioid
Endometrioid
Clear cell
IA
IA
IC
IC
IC
IIC
IIIA
IIIC
IIIC
IIIC
IIIC
IIIC
IIIC
IIIC
IV
IV
IV
IV
IV
IV
IV
(2739 ±1192)
250
ND
ND
ND
1180
4339
5187
(10 908 ± 9576)
ND
2177
22800
ND
ND
23790
ND
ND
ND
17 196
ND
II ND
I: 2088
:1 ND
ND
5637
494
ND
ND
13080
ND
British Journal ofCancer (1997) 76(9), 1221-1227
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
44
ND
ND
ND
739
745
944
1909
4489
ND
361
4664
ND
5355
825
ND
ND
14 336
1237
(73±85)
57
16
136
0
16
181
5
236
85
0
(101 ± 98)
8
89
165
283
0
93
68
(295 ± 237)
0
70
220
435
567
47
191
173
92
253
173
721
285
382
278
606
75
418
148
174
890
8
17
43
157
16
6
70
100
21
30
39
92
32
66
15
36
106
33
23
6692
33
18
164
118
3197
1852
829
4044
701
146
1778
2232
6842
550
1709
7065
211
3161
VEGF, vascular endothelial growth factor; ND, not determined; LMP, low malignant potential. Serum VEGF levels: bold type means the level above the arbitrary
cut-off of 250 pg ml-1. Numbers in parentheses are the mean ± s.d.
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Figure 3 Change of serum VEGF levels before and after the operation in
ovarian carcinoma patients (0, serous carcinoma; 0, endometrioid
carcinoma; A, clear cell carcinoma). *In a patient with stage IV serous
carcinoma, the operation was a probe laparotomy. **In a patient with stage lIl
serous carcinoma, serum VEGF was re-elevated during relapse 12 months
after the operation
found in none of the ten patients with benign cystadenoma, one of
the seven (14%) patients with LMP tumours and 10 of the 21
(48%) patients with ovarian carcinoma (P < 0.05). Serum VEGF
levels were not linearly correlated with the serum CA125 levels of
the same patient (P = 0.193) and were elevated in two of the three
patients with early-stage clear cell carcinoma whose serum CA125
levels were within the normal range (cases 21 and 22). Serial
changes in serum VEGF levels were examined in 12 carcinoma
patients (Figure 3). Serum VEGF values decreased into the normal
range 1-2 months after complete or optimal debulking surgery in
all the patients, except for a patient in whom the operation resulted
in a probe laparotomy. In one patient, re-elevation of serum VEGF
levels during relapse was also observed during the follow-up
period.
DISCUSSION
This study showed the immunohistochemical localization ofVEGF
in epithelial ovarian neoplasms. Immunostaining of VEGF local-
ized in the tumour cells of ovarian carcinoma is consistent with the
previous reports of mRNA and protein expression in cultured
ovarian cancer cells (Olson et al, 1994) and in ovarian carcinoma
tissues (Boocock et al, 1995; Abu-Jawdeh et al, 1996). In our study,
immunoreactivity for VEGF was observed in 96% of carcinomas,
52% ofLMP tumours and 33% ofbenign cystadenomas (P < 0.01),
and the frequency of strong immunostaining was significantly
higher in carcinomas (54%) than that in benign (7%) or LMP (8%)
tumours (P <0.01). Enzyme immunoassay ofVEGF in the tumour
fluid also revealed that carcinomas contained higher levels of
VEGF than benign cystadenomas did (P < 0.05). These findings
suggest that VEGF is produced more actively in ovarian carci-
nomas compared with benign and LMP ovarian tumours. Abu-
Jawdeh et al (1996) reported that VEGF levels were markedly
higher in the cyst fluids from two ovarian carcinomas and two
serous LMP tumours than those from seven serous cystadenomas.
In our series, several cases of mucinous, benign and LMP tumours
contained high concentrations of VEGF, although VEGF was
mainly immunolocalized in the luteinized theca cells of the
stroma. In normal ovaries, luteinized cells in the developing folli-
cles and corpora lutea have been reported to strongly express
VEGF (Kamat et al, 1995; Gordon et al, 1996). VEGF produced
from the luteinized stromal tissue may also contribute to the
VEGF in the tumour fluids.
In ovarian carcinomas in this series, strong immunostaining for
VEGF was more frequent in cases with an advanced FIGO stage
(P <0.05) and with positive peritoneal cytology (P <0.01). VEGF
is a 34 to 42-kDa disulphide-bonded dimeric glycoprotein that has
vascular permeability-enhancing activity 50 000 times that of hist-
amine on a molar basis (Connolly et al, 1989). The presence of
VEGF has recently been reported in ovarian follicles and ascitic
fluid from patients with ovarian hyperstimulation syndrome,
which is characterized by massive ascites and/or hydrothorax
induced by gonadotropin treatment (Krasnow et al, 1996). This is
thought to be the effect of VEGF on the permeability of vascular
endothelium in the peritoneum or the ovary itself (Neulen et al,
1995). In an animal model of peritonitis carcinomatosa, VEGF
accumulation in the peritoneal cavity paralleled tumour growth,
increased the inflow of macromolecules from the plasma to the
peritoneal cavity and the accumulation of ascitic fluid (Nagy et al,
1995). Our study revealed that VEGF accumulates in substantial
amounts not only in the tumour fluids (10 908 ± 9576 pg ml-') but
also in the ascitic fluid (2971 ±4025 pg ml-') ofovarian carcinoma
patients. Accordingly, VEGF may play an important role in
tumour progression and malignant ascites formation in ovarian
carcinomas. Ovarian carcinoma patients with strong VEGF
immunoreactivity showed poorer survival rates than those with
weak or no immunostaining. However, VEGF immunoreactivity
strongly correlates with FIGO stage, i.e. a most significant prog-
nostic factor. Therefore, the prognostic significance of VEGF is
related to its correlation with FIGO stage and is not an indepen-
dent prognostic indicator.
This study also demonstrated that serum VEGF levels were
significantly higher in ovarian carcinoma patients than in those
with benign and LMP tumours and than in normal controls
(P < 0.01). Serum VEGF levels (90 ± 92 pg ml-'; mean ± s.d.) in
the control women were consistent with a previous study on serum
VEGF levels in normal volunteers (Takano et al, 1996). When an
elevated serum VEGF level was defined as being more than
250 pg ml', because none of the control women exceeded this
value, a high serum level was observed in none ofthe patients with
benign ovarian tumours, but was seen in approximately halfofthe
ovarian cancer patients. In addition, the serum VEGF level was
not linearly correlated with CA125 level in the same patient. High
serum VEGF levels were seen in the early stage of clear cell
carcinoma patients, in which the serum CA125 levels were not
elevated. VEGF in the tumour fluids might leak into both the
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patient sera and the ascitic fluid. In several patients, however, there
was a discrepancy between the VEGF levels in the tumour fluid
and those in the ascites or in the serum. In addition, there were a
few ovarian cancerpatients with unexpectedly low levels ofVEGF
in the serum and/or tumour fluids. Therefore, the elevation of
serum VEGF levels may be influenced not only by the expression
level of VEGF but also by other factors, such as tumour vascula-
ture and/or expression of other cytokines regulating vascular
permeability. Clinically, however, the serum VEGF level
decreased when the tumour was successfully removed and was re-
elevated in a patient when the tumour relapsed. Accordingly,
VEGF could be a novel tumour marker for monitoring the ovarian
cancer patients, although examination of larger numbers of
patients is needed to confirm this conclusion.
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